Helsinn’s Riccardo Braglia on the patient perspective in cancer care

Views & Analysis
The patient perspective on cancer care

Swiss cancer care company Helsinn has become unique in the industry by remaining a family business over three generations. Paul Tunnah caught up with CEO Riccardo Braglia at JP Morgan to find out how this affords the company a distinct perspective and get his views on the biggest unmet needs for cancer patients.

 

About the interviewee

Riccardo Braglia, Helsinn Group’s vice chairman and CEO, has a wealth of over 30 years of international experience in the pharmaceutical industry. He is co-founder and Board member of Lyfebulb, USA, and a Board member of Thorne Research, Greenwich CT/USA, Wellness-Fx and Health Elements.com, all US companies. He is also active in the investment community as an advisor to the New York City-based venture capital firm Windham Ventures.

This video content was produced in partnership with Streaming Well, Healthware and Frontiers Health.

17 February, 2020


Oncology
AI in cancer care

Women in life sciences: Miruna Sasu

On International Women’s Day, pharmaphorum looks back to an interview with Miruna Sasu, PhD, CEO of COTA, a real-world data company that is advancing generative AI models for cancer care.